NIH decision letter on the Xtandi (enzalutamide) march-in petition, 21 March 2023 (2023)

Government Record · National Institutes of Health (letter to Robert Sachs and Clare Love) · March 21, 2023

National Institutes of Health (letter to Robert Sachs, 2023-03-21: NIH's decision refusing to open a march-in proceeding on Xtandi (enzalutamide), a prostate cancer drug, stating that NIH does not believe march-in would be an effective means of lowering the drug's price.

NIH does not believe that use of the march-in authority would be an effective means of lowering the price of the drug. For these reasons, NIH has determined that initiation of a march-in proceeding is not warranted in this case.

p. 2

National Institutes of Health (letter to Robert Sachs, 2023-03-21: NIH's decision refusing to open a march-in proceeding on Xtandi (enzalutamide), a prostate cancer drug, stating that NIH does not believe march-in would be an effective means of lowering the drug's price. Funder/conflicts: n/a. Maker: Astellas/Pfizer (Medivation). Comparator: n/a. The petition was filed 18 November 2021 by Robert Sachs and Clare Love, joined by KEI and UAEM; HHS referred it to NIH. NIH had declined the same request in 2016. HHS Secretary Becerra denied the follow-on administrative appeal in February 2024. The nih.gov/ott.nih.gov copy returns 404 as of retrieval, hence the advocacy-site copy; copyright status is public domain as a US government work. A 2023 Commerce/HHS statement on a draft march-in framework also exists. Study type: regulatory record.